Roche Diagnostics
Search Contact Legal Statement
Index Sitemap link to Roche

 


Now cleared for in vitro diagnostic use in the US and EU.

The world's first pharmacogenetic microarray-based test approved for clinical use.

The AmpliChip CYP450 Test provides comprehensive coverage of gene variations - including deletions and duplications - for the CYP2D6 and CYP2C19 genes, which play a major role in the metabolism of an estimated 25% of all prescription drugs. It is intended to be an aid for physicians in individualizing treatment selection and dosing for drugs metabolized through these genes.

More information/related links

Customer benefits

  • Broad allelic coverage
    High built-in sensitivity analyzing 29 polymorphisms and mutations for the 2D6 gene and 2 polymorphisms for the 2C19 gene, thereby enabling more accurate determination of patient's the genotype and predicted phenotype (poor, intermediate, extensive, or ultra rapid metabolizer). Accurately genotypes over 99% of the world's population.
  • All-in-One
    Tests for the 31 polymorphisms and mutations, including gene deletions and duplications, in a single assay.·The only test that also analyzes the functional status of gene duplications.
  • Fast results
    Analysis can normally be completed within a single eight-hour shift after receipt of patient sample at the lab.
  • Automatic Analysis
    Automatically determines genotype and predicted phenotype when used with Roche proprietary software.
  • Gold Standards
    AmpliChip microarray-based tests combine Roche's patented PCR technology, the gold standard in nucleic acid amplification, with Affymetrix leading microarray technology.

Additional features

  • Computer-assisted analysis
    Results are obtained and interpreted by computer analysis performed on a scan showing the pattern of hybridization of the patient sample to a series of probes (arrayed on the glass substrate) that are specifically complementary to either wild-type or mutant sequences.

More information/related links

© 2008, Roche Diagnostics See our Legal Statement - Privacy Policy

This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

Roche Molecular Diagnostics operates in the U.S. as the legal entity Roche Molecular Systems, Inc.